Sanofi
SNYNF
Get informed when a big investor buys or sells
+ FollowMarket Cap$106.16B
Close$
Earnings Call Q4 2025
January 29, 2026 - AI Summary
Strong Financial Performance: Sanofi reported a robust Q4 2025 with €11.3 billion in sales, achieving a 13.3% year-over-year growth. For the full year, total sales reached €43.6 billion, marking a 9.9% increase at constant exchange rates, indicating positive momentum for the company.
New Product Launches: Key product launches contributed significantly to sales. Newly launched medicines and vaccines generated €5.7 billion in sales, with Beyfortus (RSV vaccine) achieving full-year sales of €1.8 billion and ALTUVIIIO (hemophilia treatment) reaching €1.2 billion, marking its blockbuster status.
Dupixent Growth Projections: Dupixent continued to show robust growth, recording €4.2 billion in Q4 and €15.7 billion for the full year. Management highlighted expectations for continued growth in indications like COPD and CSU, despite market competition and the patent expiry approaching in March 2026, which raises concerns about potential biosimilar entries.
Exclusive for Stockcircle Pro members
Sign up
$199.38
128.9% upside
Current Fair Value
128.9% upsideUndervalued by 128.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $106.16 Billion |
|---|---|
| Enterprise Value | $124.27 Billion |
| Dividend Yield | $4.84 (5.47%) |
| Earnings per Share | $6.4 |
| Beta | 0.28 |
| Outstanding Shares | 1,196,600,000 |
Return
| Return on Equity | 9.77% |
|---|---|
| Return on Assets | 5.24% |
| Return on Invested Capital | 8.55% |
Valuation & Multiples
| P/E Ratio | 23.03 |
|---|---|
| PEG | -25.23 |
| Price to Sales | 1.74 |
| Price to Book Ratio | 1.5 |
| Enterprise Value to Revenue | 2.06 |
| Enterprise Value to EBIT | 14.97 |
| Enterprise Value to Net Income | 18 |
| Total Debt to Enterprise | 0.2 |
| Debt to Equity | 0.35 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 30, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$15.34 B
Average shareholder expectationNext Earnings Call
Expected Date
October 30, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$15.31 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Sanofi
CEO: Paul Hudson Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the c...